Par Alleges 'Shocking' Trade Secret Theft By QuVa Pharma
Par says former employees who founded QuVa used Par's trade secrets to develop a vasopressin product, which FDA has added to its list of ingredients for drug compounding.
You may also be interested in...
Par says FDA shouldn't have authorized a compounded version of Vasostrict, but parties have asked court to wait until March, when a guidance is expected that may resolve the company's concerns.
Former Pfizer employee has joined Sun Pharma as it launches ophthalmic drug and expands its specialty portfolio, which includes Phase III monoclonal antibody for treatment of psoriasis.
Details emerge on the breadth of Amgen's complaint against Coherus and former Amgen employees; trade secrets on Neulasta pricing and contract strategies allegedly stolen via USB drives.